Enzymotec (NASDAQ:ENZY) is scheduled to announce its earnings results before the market opens on Tuesday, February 20th. Analysts expect the company to announce earnings of $0.08 per share for the quarter.
Enzymotec (NASDAQ:ENZY) last released its quarterly earnings results on Wednesday, November 15th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.03). Enzymotec had a return on equity of 1.24% and a net margin of 2.32%. The firm had revenue of $13.67 million for the quarter, compared to analyst estimates of $14.36 million. On average, analysts expect Enzymotec to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Enzymotec (NASDAQ ENZY) opened at $11.85 on Tuesday. Enzymotec has a 12-month low of $6.30 and a 12-month high of $12.35. The firm has a market capitalization of $277.62, a price-to-earnings ratio of -43.89, a PEG ratio of 3.19 and a beta of 1.22.
A number of analysts have recently weighed in on the company. Jefferies Group reaffirmed a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a research report on Thursday, October 19th. Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. BidaskClub lowered Enzymotec from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Finally, Wells Fargo & Co upped their price objective on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a research report on Monday, October 30th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.75.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.